The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neulasta (Pegfilgrastim) and Biosimilar Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2029
Synopsis
The global Neulasta (Pegfilgrastim) and Biosimilar market size was valued at USD 2501.4 million in 2022 and is forecast to a readjusted size of USD 3816.3 million by 2029 with a CAGR of 6.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
This report is a detailed and comprehensive analysis for global Neulasta (Pegfilgrastim) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neulasta (Pegfilgrastim) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neulasta (Pegfilgrastim) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Viatris, Coherus, Novartis and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Neulasta (Pegfilgrastim) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand
Biosimilar
Market segment by Application
Hospital
Pharmacy
Other
Major players covered
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neulasta (Pegfilgrastim) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, with price, sales, revenue and global market share of Neulasta (Pegfilgrastim) and Biosimilar from 2018 to 2023.
Chapter 3, the Neulasta (Pegfilgrastim) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neulasta (Pegfilgrastim) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Neulasta (Pegfilgrastim) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neulasta (Pegfilgrastim) and Biosimilar.
Chapter 14 and 15, to describe Neulasta (Pegfilgrastim) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
The global Neulasta (Pegfilgrastim) and Biosimilar market size was valued at USD 2501.4 million in 2022 and is forecast to a readjusted size of USD 3816.3 million by 2029 with a CAGR of 6.2% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.
This report is a detailed and comprehensive analysis for global Neulasta (Pegfilgrastim) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Neulasta (Pegfilgrastim) and Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neulasta (Pegfilgrastim) and Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neulasta (Pegfilgrastim) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Viatris, Coherus, Novartis and Pfizer, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Neulasta (Pegfilgrastim) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Brand
Biosimilar
Market segment by Application
Hospital
Pharmacy
Other
Major players covered
Amgen
Viatris
Coherus
Novartis
Pfizer
Amneal Pharmaceutical
Fresenius Kabi
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neulasta (Pegfilgrastim) and Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, with price, sales, revenue and global market share of Neulasta (Pegfilgrastim) and Biosimilar from 2018 to 2023.
Chapter 3, the Neulasta (Pegfilgrastim) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neulasta (Pegfilgrastim) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Neulasta (Pegfilgrastim) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neulasta (Pegfilgrastim) and Biosimilar.
Chapter 14 and 15, to describe Neulasta (Pegfilgrastim) and Biosimilar sales channel, distributors, customers, research findings and conclusion.
Index1 Market Overview
1.1 Product Overview and Scope of Neulasta (Pegfilgrastim) and Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Brand
1.3.3 Biosimilar
1.4 Market Analysis by Application
1.4.1 Overview: Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Pharmacy
1.4.4 Other
1.5 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size & Forecast
1.5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Amgen Details
2.1.2 Amgen Major Business
2.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Amgen Recent Developments/Updates
2.2 Viatris
2.2.1 Viatris Details
2.2.2 Viatris Major Business
2.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Viatris Recent Developments/Updates
2.3 Coherus
2.3.1 Coherus Details
2.3.2 Coherus Major Business
2.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Coherus Recent Developments/Updates
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Novartis Recent Developments/Updates
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Pfizer Recent Developments/Updates
2.6 Amneal Pharmaceutical
2.6.1 Amneal Pharmaceutical Details
2.6.2 Amneal Pharmaceutical Major Business
2.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amneal Pharmaceutical Recent Developments/Updates
2.7 Fresenius Kabi
2.7.1 Fresenius Kabi Details
2.7.2 Fresenius Kabi Major Business
2.7.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product and Services
2.7.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Fresenius Kabi Recent Developments/Updates
3 Competitive Environment: Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer
3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Neulasta (Pegfilgrastim) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Neulasta (Pegfilgrastim) and Biosimilar Manufacturer Market Share in 2022
3.5 Neulasta (Pegfilgrastim) and Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Neulasta (Pegfilgrastim) and Biosimilar Market: Region Footprint
3.5.2 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Type Footprint
3.5.3 Neulasta (Pegfilgrastim) and Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Region (2018-2029)
4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)
4.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)
4.5 South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
7.3.1 North America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
8.3.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region
9.3.1 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
10.3.1 South America Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country
11.3.1 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers
12.2 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints
12.3 Neulasta (Pegfilgrastim) and Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Neulasta (Pegfilgrastim) and Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neulasta (Pegfilgrastim) and Biosimilar
13.3 Neulasta (Pegfilgrastim) and Biosimilar Production Process
13.4 Neulasta (Pegfilgrastim) and Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neulasta (Pegfilgrastim) and Biosimilar Typical Distributors
14.3 Neulasta (Pegfilgrastim) and Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
